Beijing United Family Hospital, Department of Pediatrics - Beijing, China.
Beijing United Family Jingbei Women and Children's Hospital, Department of Pediatrics - Beijing, China.
Rev Assoc Med Bras (1992). 2024 Feb 23;70(2):e20230636. doi: 10.1590/1806-9282.20230636. eCollection 2024.
This study aimed to explore and analyze the therapeutic effect of the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants.
This is a retrospective study. The clinical data of 68 premature infants admitted to Beijing United Family Hospital (Private Secondary Comprehensive Hospital, Chaoyang District, Beijing, China) from January 2016 to January 2022 were analyzed retrospectively. Preterm infants less than 37 weeks of gestational age admitted to the neonatal intensive care unit were included in the study. Patients with intestinal malformations, necrotizing enterocolitis, etc., who require long-term fasting were excluded. A telephone follow-up was performed 3-6 months after discharge. They were classified as treatment groups A and B according to the treatment plan. The treatment group A included parenteral nutrition, enteral nutrition, etc. In treatment group B, based on treatment group A, the premature infants were treated with Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG. The time to regain birthweight and the weight on day 30 were compared between the two groups, as was the duration of transition from parenteral nutrition to total enteral nutrition.
The time of weight regain birthweight in group B was shorter than that in group A (t=-2.560; t=-4.287; p<0.05). The increase of weight on day 30 in group B was significantly higher than that in group A (t=2.591; t=2.651; p<0.05). The time from parenteral nutrition to total enteral nutrition in group B was shorter than that in group A (z=-2.145; z=-2.236; p<0.05).
In the treatment of premature infants, the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG can have a better therapeutic effect on the underweight and malabsorption of premature infants, and this treatment method can be popularized in clinics.
本研究旨在探讨和分析动物双歧杆菌乳亚种 BB-12®和鼠李糖乳杆菌 GG 联合应用对早产儿体重不足和吸收不良的治疗效果。
这是一项回顾性研究。分析了 2016 年 1 月至 2022 年 1 月期间北京和睦家医院（北京市朝阳区私立二级综合医院）收治的 68 例早产儿的临床资料。纳入研究的早产儿胎龄小于 37 周，入新生儿重症监护病房。排除存在肠畸形、坏死性小肠结肠炎等需要长期禁食的患者。出院后进行 3-6 个月的电话随访。根据治疗方案将患者分为治疗组 A 和治疗组 B。治疗组 A 包括肠外营养、肠内营养等。治疗组 B 在治疗组 A 的基础上，给予早产儿动物双歧杆菌乳亚种 BB-12®和鼠李糖乳杆菌 GG。比较两组早产儿体重恢复至出生体重的时间和第 30 天体重，以及从肠外营养过渡到全肠内营养的时间。
B 组体重恢复至出生体重的时间短于 A 组（t=-2.560；t=-4.287；p<0.05）。B 组第 30 天体重增加量明显高于 A 组（t=2.591；t=2.651；p<0.05）。B 组从肠外营养过渡到全肠内营养的时间短于 A 组（z=-2.145；z=-2.236；p<0.05）。
在早产儿的治疗中，动物双歧杆菌乳亚种 BB-12®和鼠李糖乳杆菌 GG 的联合应用对早产儿体重不足和吸收不良有更好的治疗效果，该治疗方法可在临床推广。
